4:38 PM
 | 
Nov 12, 2018
 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE).

Twice-daily 8 mg CTP-543 met the primary endpoint of a greater proportion of patients achieving a ≥50% relative reduction in overall severity of alopecia tool (SALT) score from baseline to week 24 vs. placebo (47%...

Read the full 351 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >